Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1988 3
1989 3
1991 1
1992 1
1993 2
1995 1
1996 1
1999 1
2000 2
2001 4
2002 7
2003 3
2004 3
2005 1
2006 3
2007 2
2008 1
2009 6
2010 12
2011 11
2012 14
2013 9
2014 15
2015 9
2016 5
2017 13
2018 10
2019 10
2020 11
2021 11
2022 15
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Méndez-Sánchez N, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248211 Free article. No abstract available.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Cell-Based Therapies for Tissue Fibrosis.
Lim R, Ricardo SD, Sievert W. Lim R, et al. Among authors: sievert w. Front Pharmacol. 2017 Sep 22;8:633. doi: 10.3389/fphar.2017.00633. eCollection 2017. Front Pharmacol. 2017. PMID: 29033833 Free PMC article. Review.
The treatment of hepatitis C.
Sievert W, Batey RG. Sievert W, et al. Med J Aust. 1999 Mar 1;170(5):200-2. doi: 10.5694/j.1326-5377.1999.tb140315.x. Med J Aust. 1999. PMID: 10092915 No abstract available.
182 results